206449-93-6

Basic information

• Product Name: rac Lafutidine
• Synonyms: rac Lafutidine
• CAS NO: 206449-93-6
• Molecular Formula: C22H29N3O4S
• Molecular Weight: 431.55
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 206449-93-6.mol

Chemical Properties

• Melting Point: 94-99°C
• Boiling Point: 704.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.252
• Storage Temp.: Amber Vial, -20?C Freezer
• Solubility: Chloroform (Slightly), Dichloromethane (Slightly), DMSO (Slightly), Methanol (Sl
• PKA: 13.13±0.46(Predicted)
• Stability: Light Sensitive
• CAS DataBase Reference: rac Lafutidine(CAS DataBase Reference)
• NIST Chemistry Reference: rac Lafutidine(206449-93-6)
• EPA Substance Registry System: rac Lafutidine(206449-93-6)

Safety Data

• Hazardous Substances Data: 206449-93-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
rac Lafutidine is used as an antiulcerative agent for the treatment of gastric and duodenal ulcers, as well as other gastrointestinal disorders. It functions by blocking histamine H2-receptors, reducing gastric acid secretion and promoting healing of the ulcers.
As a second-generation histamine H2-receptor antagonist, rac Lafutidine offers improved efficacy and safety compared to first-generation agents. Its off-white solid form also contributes to its stability and ease of formulation in various pharmaceutical products.

Upstream product

• 123855-55-0 p-nitrophenyl 2-(furfurylsulfinyl)acetate 
• 110-89-4 piperidine 
• 118289-18-2 2-Bromo-4-[1,3]dioxolan-2-yl-pyridine 
• 118289-19-3 2-[4-(2-tetrahydropyranyloxy)-(Z)-2-buten-1-yloxy]-4-(1,3-dioxolan-2-yl)-pyridine 
• 118289-20-6 4-[4-(1,3-dioxolan-2-yl)-2-pyridyloxy]-(Z)-2-buten-1-ol 
• 118289-22-8 (Z)-4-(4-[1,3]Dioxolan-2-yl-pyridin-2-yloxy)-but-2-enylamine 
• 118287-95-9 N-[(Z)-4-(4-Formyl-pyridin-2-yloxy)-but-2-enyl]-2-(furan-2-ylmethanesulfinyl)-acetamide 
• 146270-01-1 2-chloro-4-(1-piperidinomethyl)-pyridine 
• 146270-02-2 (Z)-4-(Piperidin-1-ylmethyl)-2-((4-((tetrahydro-2H-pyran2-yl)oxy)but-2-en-1-yl)oxy)pyridine 
• 118289-23-9 N-[(Z)-4-(4-[1,3]Dioxolan-2-yl-pyridin-2-yloxy)-but-2-enyl]-2-(furan-2-ylmethanesulfinyl)-acetamide 
• 118289-21-7 2-[(Z)-4-(4-[1,3]Dioxolan-2-yl-pyridin-2-yloxy)-but-2-enyl]-isoindole-1,3-dione 

Relevant articles and documents

Method for manufacturing lafutidine crystal with high purity

The present invention relates to a method for manufacturing a lafutidine crystal form with high purity. The method for manufacturing a novel lafutidine crystal form of the present invention produces a desired crystal form according to temperature control after dissolution, thereby being able to be easily applied to production (scale-up) and stably manufacture the lafutidine crystal form with high purity.

Preparation method and application of lafutidine and intermediate thereof

The invention relates to a preparation method and application of lafutidine and an intermediate thereof. The preparation method of the lafutidine intermediate comprises the following steps: the formula is as shown in the specification, wherein a compound shown as a formula (I) reacts in the presence of an alcohol amine type organic base and at least one type of other alkaline compound, so as to obtain the lafutidine intermediate shown as a formula (II). The preparation method of the lafutidine intermediate, disclosed by the invention, is safe and environmentally friendly, and avoids hidden dangers of safety production, caused by the fact that hydrazine hydrate, methylamine, ethanediamine, hydroxylamine hydrochloride and the like are used; the obtained lafutidine intermediate can be directly subjected to a condensation reaction to obtain the lafutidine, without the need of being further purified; the product is stable in quality and high in purity and does not contain a dihydrolafutidine impurity and the content of total impurities is lower than 0.15%; and the complicated purification is avoided and the whole process is high in yield and low in cost.

Increasing the Purity of Lafutidine Using a suicide Substrate

When preparing lafutidine, we found that the main impurity was dihydrolafutidine. On the basis of the chemical structure of dihydrolafutidine and the mechanism of its production, we decided to use a suicide substrate in the drug preparation to increase the purity of lafutidine. By calculating the energy barrier of the reduction reaction with a quantum-chemical method and evaluating the appropriate physicochemical properties of the terminal olefins, we chose 1-hexene as the suicide substrate to effectively control the formation of dihydrolafutidine in the synthesis of lafutidine. The experimental results showed that the content of the impurity, dihydrolafutidine, decreased from 1.5% to less than 0.05%, proving that using a suicide substrate is an effective method to reduce the formation of the relevant byproduct in drug production. In addition, this method is operationally simple and is suitable for industrial applications.

Lafutidine isomer preparation method

The invention provides a preparation method of a lafutidine isomer, and belongs to the field of pharmaceutical technologies. The preparation method comprises the following steps: carrying out sulfonylation reaction on raw materials, so that a sulfonated product is obtained; reacting the sulfonated product with an amide; and oxidizing the obtained product by using hydrogen peroxide, so that trans-lafutidine can be obtained. The method is used for solving the problem of standard product preparation of trans-lafutidine, and obtained products can be applied to the quality control of lafutidine in production.

Lafutidine hydroxylamine hydrochloride method of preparation

The invention relates to a novel chemical synthetic method for lafutidine, and in particular relates to a method for preparing the lafutidine from hydroxylamine hydrochloride serving as aminolysis reagent. The method comprises the following steps of: (1) reacting a compound in a formula 4 with the hydroxylamine hydrochloride and sodium hydroxide so as to obtain a compound in a formula 2; (2) carrying out condensation on the compound in the formula 2 and a compound in a formula 3 so as to obtain the lafutidine in a formula 1. The whole preparation process is as shown in the specification. When in preparation of the key intermediate the compound in the formula 2, the hydroxylamine hydrochloride is chosen for substituting other reagents for aminolysis reaction, and the prepared lafutidine product has higher purity and can reach 99.88%; compared with the condition that the aminolysis reagent is removed from the intermediate, the hydroxylamine is easier to remove; and furthermore, the hydroxylamine hydrochloride is a solid reagent, has high purity and high stability, and industrial production is more easily realized.

A novel histamine 2(H2) receptor antagonist with gastroprotective activity. II. Synthesis and pharmacological evaluation of 2-furfuryl-thio and 2-furfurylsulfinyl acetamide derivatives with heteroaromatic rings

We recently found that N-[3-[3- (piperidinomethyl)phenoxy]propyl]acetamide derivatives with a thioether function showed gastric anti-secretory and gastroprotective activities and that the thioether function (particularly furfurylthio or furfurylsulfinyl) was essential for gastroprotection. In the present study, a series of 2- furfurylthio and 2-furfurylsulfinyl acetamide derivatives were synthesized and evaluated for histamine H2 receptor antagonistic activity, gastric anti- secretory activity and gastroprotective action. Based on the structure of N- [3-[3-(piperidinomethyl)phenoxy]propyl]acetamide, we designed compounds, in which the 3-(piperidinomethyl)phenoxy part is substituted with many types of heteroaromatic ring attached to the tertiary amine and the propyl group is replaced with other carbon linkages. Structure-activity relationships are discussed. 2-Furfurylsulfinyl-N-[4-[4-(piperidinomethyl)-2-pyridyloxy]-(Z)- 2-butenyl]acetamide was the most potent among the tested compounds and was given the code designation FRG-8813.